Coverage
-
December 02, 2022
The Federal Circuit on Friday declined to review en banc a panel's decision that three Stanford University diagnostic patents licensed to a developer of commercial tests for kidney transplant rejections are ineligible for protection.
4 other articles on this case.
View all »